Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. (20th December 2012)
- Record Type:
- Journal Article
- Title:
- Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. (20th December 2012)
- Main Title:
- Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis
- Authors:
- Grasselli, G
Rossi, S
Musella, A
Gentile, A
Loizzo, S
Muzio, L
Di Sanza, C
Errico, F
Musumeci, G
Haji, N
Fresegna, D
Sepman, H
De Chiara, V
Furlan, R
Martino, G
Usiello, A
Mandolesi, G
Centonze, D - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph2178-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Glutamate transmission is dysregulated in both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), the animal model of MS. A characteristic of EAE is increased glutamate transmission associated with up‐regulation of AMPA receptors. However, little is known about the role of NMDA receptors in the synaptic modifications induced by EAE.</p> </sec> <sec id="bph2178-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>The contribution of NMDA receptors to the alterations of glutamate transmission and disease severity in EAE mice was assessed by means of neurophysiological, morphological, Western blot, metabolic and clinical score assessments.</p> </sec> <sec id="bph2178-sec-0003" sec-type="section"> <title>Key Results</title> <p>In our EAE mice, there was an NMDA receptor‐dependent increase of glutamate release, associated with marked activation of the astroglia. Presynaptic NMDA receptors became overactive during EAE, increasing synaptic glutamate release by a mechanism dependent on voltage‐gated sodium channels. By means of NAD(P)H autofluorescence analysis, we also found that EAE has a glutamate and NMDA receptor‐dependent dysfunction of mitochondrial activity, which is known to contribute to the neurodegenerative damage of MS and EAE. Furthermore, pharmacological<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph2178-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Glutamate transmission is dysregulated in both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), the animal model of MS. A characteristic of EAE is increased glutamate transmission associated with up‐regulation of AMPA receptors. However, little is known about the role of NMDA receptors in the synaptic modifications induced by EAE.</p> </sec> <sec id="bph2178-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>The contribution of NMDA receptors to the alterations of glutamate transmission and disease severity in EAE mice was assessed by means of neurophysiological, morphological, Western blot, metabolic and clinical score assessments.</p> </sec> <sec id="bph2178-sec-0003" sec-type="section"> <title>Key Results</title> <p>In our EAE mice, there was an NMDA receptor‐dependent increase of glutamate release, associated with marked activation of the astroglia. Presynaptic NMDA receptors became overactive during EAE, increasing synaptic glutamate release by a mechanism dependent on voltage‐gated sodium channels. By means of NAD(P)H autofluorescence analysis, we also found that EAE has a glutamate and NMDA receptor‐dependent dysfunction of mitochondrial activity, which is known to contribute to the neurodegenerative damage of MS and EAE. Furthermore, pharmacological blockade of NMDA receptors <italic>in vivo</italic> ameliorated both synaptic transmission defects and of the clinical disease course of EAE mice, while EAE induced in mice with a genetically enhanced NMDA receptor signalling had opposite effects.</p> </sec> <sec id="bph2178-sec-0004" sec-type="section"> <title>Conclusions and Implications</title> <p>Our data, showing both sensitization of NMDA receptors and their involvement in the progression of the EAE disease, supggest that pharmacological impairment of NMDA receptor signalling would be a component of a neuroprotection strategy in MS.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 168:Number 2(2013:Jan.)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 168:Number 2(2013:Jan.)
- Issue Display:
- Volume 168, Issue 2 (2013)
- Year:
- 2013
- Volume:
- 168
- Issue:
- 2
- Issue Sort Value:
- 2013-0168-0002-0000
- Page Start:
- 502
- Page End:
- 517
- Publication Date:
- 2012-12-20
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/j.1476-5381.2012.02178.x ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 2992.xml